You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChlorprothixene
Accession NumberDB01239  (APRD00718)
TypeSmall Molecule
GroupsApproved, Withdrawn
DescriptionChlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.
Structure
Thumb
Synonyms
Alpha-Chlorprothixene
Chlorprothixen
Chlorprothixine
Chlorprotixen
Chlorprotixene
Chlorprotixine
Chlothixen
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ClothixenYoshitomi
CloxanOrion
TaractanRoche
Brand mixturesNot Available
SaltsNot Available
Categories
UNII9S7OD60EWP
CAS number113-59-7
WeightAverage: 315.86
Monoisotopic: 315.084847978
Chemical FormulaC18H18ClNS
InChI KeyWSPOMRSOLSGNFJ-VGOFMYFVSA-N
InChI
InChI=1S/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7+
IUPAC Name
[3-(2-chloro-9H-thioxanthen-9-ylidene)propyl]dimethylamine
SMILES
[H]C(CCN(C)C)=C1C2=CC(Cl)=CC=C2SC2=C1C=CC=C2
Pharmacology
IndicationFor treatment of psychotic disorders (e.g. schizophrenia) and of acute mania occuring as part of bipolar disorders.
Structured Indications Not Available
PharmacodynamicsChlorprothixene is a typical antipsychotic drug of the thioxanthine class. It has a low antipsychotic potency (half to 2/3 of chlorpromazine). An intrinsic antidepressant effect of chlorprothixene has been discussed, but not proven yet. Likewise, it is unclear, if chlorprothixene has genuine analgesic effects. An antiemetic effect, as with most antipsychotics, exists. It is used in the treatment of nervous, mental, and emotional conditions. Improvement in such conditions is thought to result from the effect of the medicine on nerve pathways in specific areas of the brain. Chlorprothixene has a strong sedative activity with a high incidence of anticholinergic side-effects. Chlorprothixene is structurally related to chlorpromazine, with which it shares in principal all side effects. Allergic side-effects and liver damage seem to appear with an appreciable lower frequency.
Mechanism of actionChlorprothixene blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
D(1A) dopamine receptorProteinyes
antagonist
HumanP21728 details
D(3) dopamine receptorProteinyes
antagonist
HumanP35462 details
5-hydroxytryptamine receptor 2AProteinyes
antagonist
HumanP28223 details
5-hydroxytryptamine receptor 2BProteinyes
antagonist
HumanP41595 details
5-hydroxytryptamine receptor 2CProteinyes
antagonist
HumanP28335 details
Histamine H1 receptorProteinunknown
antagonist
HumanP35367 details
Muscarinic acetylcholine receptor M1Proteinno
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinno
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinno
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M4Proteinno
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M5Proteinno
antagonist
HumanP08912 details
Related Articles
AbsorptionIncomplete bioavailability.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic

Route of eliminationNot Available
Half life8 to 12 hours
ClearanceNot Available
ToxicitySymptoms of overdose include difficulty in breathing (severe), dizziness (severe), drowsiness (severe), muscle trembling, jerking, stiffness, or uncontrolled movements (severe), small pupils, unusual excitement, and unusual tiredness or weakness (severe).
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamineChlorprothixene may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetamineChlorprothixene may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetamineChlorprothixene may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineChlorprothixene may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with 7-Nitroindazole.Experimental
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Chlorprothixene.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Chlorprothixene.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Chlorprothixene.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Agomelatine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Chlorprothixene.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorprothixene.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Chlorprothixene.Approved, Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Chlorprothixene.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chlorprothixene.Approved, Illicit, Investigational
AmantadineThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Chlorprothixene.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Chlorprothixene.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Amperozide.Experimental
AmphetamineChlorprothixene may decrease the stimulatory activities of Amphetamine.Approved, Illicit
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Chlorprothixene.Approved
ApomorphineThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Apomorphine.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorprothixene.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Chlorprothixene.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Asenapine.Approved
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Chlorprothixene.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Chlorprothixene.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Chlorprothixene.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Azaperone.Vet Approved
AzelastineChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Chlorprothixene.Approved
BenzphetamineChlorprothixene may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Benzyl alcohol.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Chlorprothixene.Approved
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Chlorprothixene.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Chlorprothixene.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved
BromazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Bromazepam.Approved, Illicit
BromocriptineThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chlorprothixene.Approved, Investigational
BuprenorphineChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Chlorprothixene.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chlorprothixene.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorprothixene.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Chlorprothixene.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Chlorprothixene.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Chlorprothixene.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Chlorprothixene.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Chlorprothixene.Approved
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Chlorprothixene.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Chlorprothixene.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Chlorprothixene.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Chlorprothixene.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chlorprothixene.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Chlorprothixene.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chlorprothixene.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Chlorphenamine.Approved
ChlorphentermineChlorprothixene may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Chlorzoxazone.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Chlorprothixene.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chlorprothixene.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Chlorprothixene.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Chlorprothixene.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Chlorprothixene.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Chlorprothixene.Approved
ClemastineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Chlorprothixene.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Chlorprothixene.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Chlorprothixene.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Chlorprothixene.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chlorprothixene.Approved, Illicit
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Chlorprothixene.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Chlorprothixene.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Chlorprothixene.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorprothixene.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Chlorprothixene.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Chlorprothixene.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Chlorprothixene.Approved
CyclizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorprothixene.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Chlorprothixene.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Cyproheptadine.Approved
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Chlorprothixene.Approved
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Chlorprothixene.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Chlorprothixene.Approved
DantroleneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Chlorprothixene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chlorprothixene.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dapoxetine.Investigational
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Chlorprothixene.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Chlorprothixene.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Chlorprothixene.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Chlorprothixene.Approved
DesipramineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Chlorprothixene.Approved
DetomidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Chlorprothixene.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorprothixene.Approved, Vet Approved
DextroamphetamineChlorprothixene may decrease the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Chlorprothixene.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorprothixene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Chlorprothixene.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Chlorprothixene.Approved, Illicit, Vet Approved
DiethylpropionChlorprothixene may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Chlorprothixene.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Chlorprothixene.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Chlorprothixene.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chlorprothixene.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Chlorprothixene.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Chlorprothixene.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chlorprothixene.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorprothixene.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Chlorprothixene.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Chlorprothixene.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Chlorprothixene.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Chlorprothixene.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Chlorprothixene.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chlorprothixene.Approved
EcgonineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Chlorprothixene.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Chlorprothixene.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Chlorprothixene.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Entacapone.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Chlorprothixene.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Chlorprothixene.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Chlorprothixene.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Chlorprothixene.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Chlorprothixene.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Chlorprothixene.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Chlorprothixene.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Chlorprothixene.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Chlorprothixene.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chlorprothixene.Approved
EthanolChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chlorprothixene.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Chlorprothixene.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorprothixene.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Chlorprothixene.Approved
EtorphineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Chlorprothixene.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Chlorprothixene.Approved
EzogabineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorprothixene.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Chlorprothixene.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Chlorprothixene.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Chlorprothixene.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Chlorprothixene.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chlorprothixene.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chlorprothixene.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chlorprothixene.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Chlorprothixene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Chlorprothixene.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Chlorprothixene.Approved, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorprothixene.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Chlorprothixene.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Chlorprothixene.Approved
GepironeThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Glutethimide.Approved, Illicit
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Chlorprothixene.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Chlorprothixene.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Chlorprothixene.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Chlorprothixene.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Chlorprothixene.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Hexobarbital.Approved
HydrocodoneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorprothixene.Approved, Illicit
Hydroxyamphetamine hydrobromideChlorprothixene may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Chlorprothixene.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Chlorprothixene.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Chlorprothixene.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Chlorprothixene.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Chlorprothixene.Approved
IndalpineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Chlorprothixene.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Chlorprothixene.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Chlorprothixene.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Chlorprothixene.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Chlorprothixene.Approved, Vet Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Chlorprothixene.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Chlorprothixene.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Chlorprothixene.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Chlorprothixene.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Chlorprothixene.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Chlorprothixene.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Chlorprothixene.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Chlorprothixene.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Chlorprothixene.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Chlorprothixene.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Chlorprothixene.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Chlorprothixene.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorprothixene.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Chlorprothixene.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorprothixene.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Chlorprothixene.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Chlorprothixene.Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Chlorprothixene.Approved, Investigational
LisdexamfetamineChlorprothixene may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Chlorprothixene.Approved
LofentanilThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Lofentanil.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Chlorprothixene.Approved
LoratadineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chlorprothixene.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Chlorprothixene.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Chlorprothixene.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chlorprothixene.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Lu AA21004.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Chlorprothixene.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Chlorprothixene.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Melperone.Approved
MephedroneChlorprothixene may decrease the stimulatory activities of Mephedrone.Investigational
MephentermineChlorprothixene may decrease the stimulatory activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chlorprothixene.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorprothixene.Approved, Illicit
MequitazineChlorprothixene may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chlorprothixene.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorprothixene.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineChlorprothixene may decrease the stimulatory activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorprothixene.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Chlorprothixene.Approved
MethotrimeprazineChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chlorprothixene.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chlorprothixene.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Chlorprothixene.Approved, Investigational
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Chlorprothixene.Approved, Investigational
MetyrosineChlorprothixene may increase the sedative activities of Metyrosine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Chlorprothixene.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Chlorprothixene.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Chlorprothixene.Approved
MirtazapineChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Chlorprothixene.Approved, Investigational
MMDAChlorprothixene may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Chlorprothixene.Approved
MolindoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Molindone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Chlorprothixene.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorprothixene.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Chlorprothixene.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorprothixene.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Chlorprothixene.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Chlorprothixene.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Chlorprothixene.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Chlorprothixene.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Chlorprothixene.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Chlorprothixene.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Chlorprothixene.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Chlorprothixene.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Chlorprothixene.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Nortriptyline.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Chlorprothixene.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Chlorprothixene.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chlorprothixene.Approved
OpiumThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Opium.Approved, Illicit
OrphenadrineChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Chlorprothixene.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorprothixene.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chlorprothixene.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorprothixene.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorprothixene.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Chlorprothixene.Approved, Investigational
ParaldehydeChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Chlorprothixene.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Chlorprothixene.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorprothixene.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chlorprothixene.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved
PerazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chlorprothixene.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorprothixene.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Chlorprothixene.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Chlorprothixene.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Phenoxyethanol.Approved
PhentermineChlorprothixene may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Chlorprothixene.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pipotiazine.Approved
PiribedilThe therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Chlorprothixene.Approved
PizotifenThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Chlorprothixene.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Chlorprothixene.Approved
PramipexoleChlorprothixene may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Chlorprothixene.Approved
PrazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Chlorprothixene.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chlorprothixene.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Chlorprothixene.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Chlorprothixene.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Chlorprothixene.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorprothixene.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Chlorprothixene.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chlorprothixene.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Chlorprothixene.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Chlorprothixene.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Chlorprothixene.Approved
PSD502The risk or severity of adverse effects can be increased when Chlorprothixene is combined with PSD502.Investigational
PseudoephedrineChlorprothixene may decrease the stimulatory activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Chlorprothixene.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Chlorprothixene.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Chlorprothixene.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Chlorprothixene.Approved
RacloprideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Chlorprothixene.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Chlorprothixene.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Chlorprothixene.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorprothixene.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chlorprothixene.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Chlorprothixene.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Chlorprothixene.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Chlorprothixene.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Chlorprothixene.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ritanserin.Investigational
RitobegronChlorprothixene may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Chlorprothixene.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Chlorprothixene.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Chlorprothixene.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Chlorprothixene.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Romifidine.Vet Approved
RopiniroleChlorprothixene may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chlorprothixene.Approved
RotigotineChlorprothixene may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorprothixene.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sage 547.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Chlorprothixene.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Chlorprothixene.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chlorprothixene.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Chlorprothixene.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Chlorprothixene.Approved
SertindoleThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Chlorprothixene.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorprothixene.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Chlorprothixene.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Chlorprothixene.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Chlorprothixene.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Chlorprothixene.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Chlorprothixene.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Chlorprothixene.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Chlorprothixene.Experimental
StiripentolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorprothixene.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Chlorprothixene.Approved, Investigational
SuvorexantChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Chlorprothixene.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Chlorprothixene.Approved
TandospironeThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Chlorprothixene.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Chlorprothixene.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Chlorprothixene.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Chlorprothixene.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Chlorprothixene.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Chlorprothixene.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Chlorprothixene.Approved
TetracaineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tetrodotoxin.Investigational
ThalidomideChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chlorprothixene.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Chlorprothixene.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chlorprothixene.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Chlorprothixene.Approved
TiletamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Chlorprothixene.Approved
TizanidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Tolcapone.Approved, Withdrawn
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Chlorprothixene.Approved
TopiramateThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Chlorprothixene.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Chlorprothixene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorprothixene.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chlorprothixene.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Chlorprothixene.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Chlorprothixene.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Chlorprothixene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorprothixene.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chlorprothixene.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Chlorprothixene.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Chlorprothixene.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Chlorprothixene.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Chlorprothixene.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Chlorprothixene.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Chlorprothixene.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Chlorprothixene.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Chlorprothixene.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Chlorprothixene.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Chlorprothixene.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Chlorprothixene.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorprothixene.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Chlorprothixene.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Chlorprothixene.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Chlorprothixene.Approved, Investigational
ZolpidemChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Chlorprothixene.Approved
ZotepineThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.
References
Synthesis Reference

Sprague, J.M. and Engelhardt, E.L.; US. Patent 2,951,082; August 30, 1960; assigned to
Merck & Co., Inc.
Schlapfer, R. and Spiegelberg, H.; US. Patent 3,115,502; December 24,1963; assigned to Hoffmann-LaRoche Inc.

US3046283
General ReferencesNot Available
External Links
ATC CodesN05AF03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (63.3 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9899
Blood Brain Barrier+0.95
Caco-2 permeable+0.7404
P-glycoprotein substrateSubstrate0.8042
P-glycoprotein inhibitor IInhibitor0.8407
P-glycoprotein inhibitor IIInhibitor0.8884
Renal organic cation transporterInhibitor0.72
CYP450 2C9 substrateNon-substrate0.7199
CYP450 2D6 substrateSubstrate0.6845
CYP450 3A4 substrateSubstrate0.7096
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8308
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.768
Ames testNon AMES toxic0.7084
CarcinogenicityNon-carcinogens0.8714
BiodegradationNot ready biodegradable0.9838
Rat acute toxicity3.1665 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8117
hERG inhibition (predictor II)Inhibitor0.7373
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point153-154Sprague, J.M. and Engelhardt, E.L.; US. Patent 2,951,082; August 30, 1960; assigned to Merck & Co., Inc. Schlapfer, R. and Spiegelberg, H.; US. Patent 3,115,502; December 24,1963; assigned to Hoffmann-LaRoche Inc.
water solubility0.295 mg/LNot Available
logP5.18HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.000366 mg/mLALOGPS
logP5.42ALOGPS
logP5.07ChemAxon
logS-5.9ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity104.66 m3·mol-1ChemAxon
Polarizability35.85 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.22 KB)
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as thioxanthenes. These are organic polycyclic compounds containing a thioxanthene moiety, which is an aromatic tricycle derived from xanthene by replacing the oxygen atom with a sulfur atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiopyrans
Sub Class1-benzothiopyrans
Direct ParentThioxanthenes
Alternative Parents
Substituents
  • Thioxanthene
  • Diarylthioether
  • Chlorobenzene
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Froimowitz M, Cody V: Biologically active conformers of phenothiazines and thioxanthenes. Further evidence for a ligand model of dopamine D2 receptor antagonists. J Med Chem. 1993 Jul 23;36(15):2219-27. [PubMed:8101879 ]
  2. Fux M, Belmaker RH: A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. Isr J Psychiatry Relat Sci. 1991;28(1):37-40. [PubMed:1830565 ]
  3. von Coburg Y, Kottke T, Weizel L, Ligneau X, Stark H: Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics. Bioorg Med Chem Lett. 2009 Jan 15;19(2):538-42. doi: 10.1016/j.bmcl.2008.09.012. Epub 2008 Sep 7. [PubMed:19091563 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Fux M, Belmaker RH: A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. Isr J Psychiatry Relat Sci. 1991;28(1):37-40. [PubMed:1830565 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Fux M, Belmaker RH: A controlled comparative study of chlorprothixene vs. haloperidol in chronic schizophrenia. Isr J Psychiatry Relat Sci. 1991;28(1):37-40. [PubMed:1830565 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Antkiewicz-Michaluk L: The influence of chronic treatment with antidepressant neuroleptics on the central serotonin system. Pol J Pharmacol Pharm. 1986 Jul-Aug;38(4):359-70. [PubMed:3774629 ]
  2. Wander TJ, Nelson A, Okazaki H, Richelson E: Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro. Eur J Pharmacol. 1987 Nov 10;143(2):279-82. [PubMed:2891550 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Cusack B, Nelson A, Richelson E: Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994 May;114(4):559-65. [PubMed:7855217 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23